ECSP099177A - Derivados de quinazolinona e isoquinolinona - Google Patents

Derivados de quinazolinona e isoquinolinona

Info

Publication number
ECSP099177A
ECSP099177A EC2009009177A ECSP099177A ECSP099177A EC SP099177 A ECSP099177 A EC SP099177A EC 2009009177 A EC2009009177 A EC 2009009177A EC SP099177 A ECSP099177 A EC SP099177A EC SP099177 A ECSP099177 A EC SP099177A
Authority
EC
Ecuador
Prior art keywords
quinazolinona
isoquinolinona
derivatives
present
quinazolinone
Prior art date
Application number
EC2009009177A
Other languages
English (en)
Inventor
Duncan Robert Mcarthur
Jeffrey Letourneau
Koc-Kan Ho
Michael Ohlmeyer
Patrick Jokiel
Susan Elizabeth Napier
Paul David Ratcliffe
Jeremiah Fiona
Schulz Jurgen
Original Assignee
Organon Nv
Pharmacopeia Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv, Pharmacopeia Llc filed Critical Organon Nv
Publication of ECSP099177A publication Critical patent/ECSP099177A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

La presente invención se refiere a un derivado de quinazolinona o isoquinolinona de fórmula I: o una sal o solvato farmacéuticamente aceptable del mismo, donde R1, R2, R3, R4 y X son como se definió en la reivindicación 1. La presente invención se refiere además a una composición farmacéutica que comprende una quinazolinona o isoquinolinona de acuerdo con la presente invención, y a su uso en terapia.
EC2009009177A 2006-09-11 2009-03-11 Derivados de quinazolinona e isoquinolinona ECSP099177A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84371806P 2006-09-11 2006-09-11

Publications (1)

Publication Number Publication Date
ECSP099177A true ECSP099177A (es) 2009-06-30

Family

ID=39184483

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009177A ECSP099177A (es) 2006-09-11 2009-03-11 Derivados de quinazolinona e isoquinolinona

Country Status (20)

Country Link
US (1) US7820649B2 (es)
EP (1) EP2069315B1 (es)
JP (1) JP5256202B2 (es)
KR (1) KR20090107994A (es)
CN (1) CN101600698B (es)
AR (1) AR062731A1 (es)
AT (1) ATE523500T1 (es)
AU (1) AU2007296634B2 (es)
CA (1) CA2663161C (es)
CL (1) CL2007002635A1 (es)
CO (1) CO6160322A2 (es)
EC (1) ECSP099177A (es)
IL (1) IL197530A0 (es)
MX (1) MX2009002686A (es)
NO (1) NO20091012L (es)
NZ (1) NZ575426A (es)
PE (1) PE20080841A1 (es)
RU (1) RU2009113612A (es)
TW (1) TW200827352A (es)
WO (1) WO2008033764A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010229035A (ja) * 2007-08-01 2010-10-14 Taisho Pharmaceutical Co Ltd ピリドピリミジン−４−オン誘導体
WO2009130231A1 (en) * 2008-04-24 2009-10-29 Glaxo Group Limited Pyrrolo [1, 2-a] pyrazine derivatives as vasopressin vib receptor antagonists
JP5369721B2 (ja) * 2009-01-30 2013-12-18 大正製薬株式会社 ピリドピリミジン−４−オン誘導体
MX2012004289A (es) * 2009-10-13 2012-06-12 Msd Oss Bv Derivados de azina condensada para el tratamiento de enfermedades relacionadas con el receptor de acetilcolina.
WO2012043791A1 (ja) 2010-10-01 2012-04-05 大正製薬株式会社 １，２，４-トリアゾロン誘導体
MY168930A (en) 2011-10-27 2019-01-09 Taisho Pharmaceutical Co Ltd Azole derivative
SG11201406182PA (en) 2012-03-30 2014-10-30 Taisho Pharmaceutical Co Ltd Fused azole derivative
MA37756B1 (fr) 2012-06-13 2018-09-28 Hoffmann La Roche Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane
EP3590940B1 (en) 2012-09-25 2021-06-09 F. Hoffmann-La Roche AG Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
MA38982A1 (fr) 2013-11-26 2017-09-29 Hoffmann La Roche Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
CN106103446B (zh) 2014-03-26 2019-07-30 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物
MX2016010675A (es) 2014-03-26 2016-11-10 Hoffmann La Roche Compuestos condensados de [1,4]diazepina como inhibidores de produccion de la autotaxina (atx) y acido lisofosfatidico (lpa).
US10030010B2 (en) 2014-08-04 2018-07-24 Sandoz Ag Route of synthesis for the preparation of suvorexant
WO2016034703A1 (en) 2014-09-05 2016-03-10 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
MA41898A (fr) * 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CN108026077B (zh) 2015-09-04 2021-11-05 豪夫迈·罗氏有限公司 苯氧基甲基衍生物
MA42923A (fr) 2015-09-24 2021-04-28 Hoffmann La Roche Composés bicycliques comme inhibiteurs mixtes de atx/ca
MA42918A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
WO2017050792A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
JP6845230B2 (ja) 2015-09-24 2021-03-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ デュアルａｔｘ／ｃａ阻害剤としての新規な二環式化合物
LT3386591T (lt) * 2015-12-09 2020-10-12 Cadent Therapeutics, Inc. Heteroaromatiniai nmda receptoriaus moduliatoriai ir jų panaudojimas
EP3386990B1 (en) 2015-12-09 2023-04-19 Novartis AG Thienopyrimidinone nmda receptor modulators and uses thereof
EP3558318B1 (en) 2016-12-22 2023-12-20 Novartis AG Nmda receptor modulators and uses thereof
MA49879A (fr) 2017-03-16 2020-06-24 Hoffmann La Roche Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
IL280474B2 (en) 2018-08-03 2023-09-01 Cadent Therapeutics Inc Heteroaromatic nmda receptor modulators and their uses
CN111100063B (zh) * 2018-10-25 2022-05-17 南京药石科技股份有限公司 一种合成2-氟甲基取代的吡咯烷、哌啶以及哌嗪衍生物的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2506767A1 (fr) 1981-05-26 1982-12-03 Synthelabo Derives heterocycliques d'amidoximes, leur preparation et leur application en therapeutique
CA2288140C (en) 1997-04-25 2007-04-03 Janssen Pharmaceutica N.V. Farnesyltransferase inhibiting quinazolinones
IL139199A (en) 1999-11-02 2006-10-31 Nihon Nohyaku Co Ltd Derivatives of aminoquinazolinone (thion) or their salts, their intermediates, pesticides and method of use
FR2804114B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2842527B1 (fr) 2002-07-19 2005-01-28 Sanofi Synthelabo Derives d'acyloxypyrolidine, leur preparation et leur application en therapeutique
KR100843053B1 (ko) * 2004-01-16 2008-07-01 에프. 호프만-라 로슈 아게 중추 신경계 질환의 치료를 위한 5-하이드록시트립트아민수용체(5-ｈｔ)의 조절제로서1-벤질-5-피페라진-1-일-3,4-다이하이드로-1ｈ-퀴나졸린-2-온 유도체 및 각각의1ｈ-벤조(1,2,6)티아다이아진-2,2-다이옥사이드 및1,4-다이하이드로-벤조(ｄ)(1,3)옥사진-2-온 유도체
CN1960977B (zh) * 2004-05-31 2010-07-21 万有制药株式会社 喹唑啉衍生物
WO2006012577A2 (en) * 2004-07-22 2006-02-02 Bayer Pharmaceuticals Corporation Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake
TW200643015A (en) * 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
MX2009002685A (es) * 2006-09-11 2009-10-13 Organon Nv Derivados de acetamida de (2- (1-oxo-1h-isoquinolin-2-il).

Also Published As

Publication number Publication date
CA2663161A1 (en) 2008-03-20
US7820649B2 (en) 2010-10-26
CL2007002635A1 (es) 2009-10-23
EP2069315A2 (en) 2009-06-17
JP2010502746A (ja) 2010-01-28
CA2663161C (en) 2014-10-28
RU2009113612A (ru) 2010-10-20
NO20091012L (no) 2009-03-26
CN101600698A (zh) 2009-12-09
AU2007296634A1 (en) 2008-03-20
NZ575426A (en) 2010-09-30
CN101600698B (zh) 2012-01-11
WO2008033764A3 (en) 2008-12-18
EP2069315B1 (en) 2011-09-07
MX2009002686A (es) 2009-10-13
AR062731A1 (es) 2008-11-26
KR20090107994A (ko) 2009-10-14
US20080090802A1 (en) 2008-04-17
TW200827352A (en) 2008-07-01
WO2008033764A2 (en) 2008-03-20
IL197530A0 (en) 2009-12-24
JP5256202B2 (ja) 2013-08-07
AU2007296634B2 (en) 2012-09-20
ATE523500T1 (de) 2011-09-15
PE20080841A1 (es) 2008-06-14
EP2069315A4 (en) 2010-11-03
CO6160322A2 (es) 2010-05-20

Similar Documents

Publication Publication Date Title
ECSP099177A (es) Derivados de quinazolinona e isoquinolinona
ECSP088871A (es) Derivados de triazolopirazina
UY29963A1 (es) Compuestos terapéuticos: piridinas y pirazinas como andamios
TW200626558A (en) Indazolone derivatives
EA201170249A1 (ru) 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
GT200600518A (es) Derivados de pirimidina
ECSP066314A (es) Derivados piridilo y su uso como agentes terapéuticos
CR9587A (es) Derivados de piridazina
BRPI0412851A (pt) benzamidazóis de n-metila-substituìdos
NO20074441L (no) 1-benzylindol-2-karboksamidderivater
UY30438A1 (es) Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
BRPI0915084B8 (pt) composto, e, composição farmacêutica
CR9214A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
BRPI0518993A2 (pt) composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto
ECSP066693A (es) Derivados de bencimidazol
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
UY28917A1 (es) Derivados de tetrahidroisoquinolilsulfonamidas composiciones farmaceuticas y su uso terapeutico
GT200600081A (es) Derivados de acetilenno
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
TW200740764A (en) Pyrazolone derivatives
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
BRPI0519267A2 (pt) derivado de quinolina, seu uso, produÇço e medicamento contendo o mesmo
HN2011002578A (es) Nuevos derivados de compuestos de [3,2-c]pirazol esteroidal con actividad clucocorticoide.